IMP3 can predict aggressive behaviour of lung adenocarcinoma

Diagnostic Pathology

Volumn 7, Issue 1, 2012, Pages

  Beljan Perak, Renata ^a   Durdov, Merica G ^a   Capkun, Vesna ^a   Ivcevic, Veljka ^a   Pavlovic, Antonia ^a   Soljic, Violeta ^b   Peric, Mari ^a  

^a UNIVERSITY HOSPITAL SPLIT   (Croatia)

^b UNIVERSITY OF MOSTAR   (Bosnia and Herzegovina)

Author keywords

Aggressive phenotype; IMP 3; Lung adenocarcinoma; Napsin A; TTF 1

Indexed keywords

ASPARTIC PROTEINASE; IMP3 PROTEIN, HUMAN; NAPSA PROTEIN, HUMAN; NUCLEAR PROTEIN; PARAFFIN; RNA BINDING PROTEIN; THYROID NUCLEAR FACTOR 1; TRANSCRIPTION FACTOR; TUMOR MARKER;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; BIOPSY; BRONCHOSCOPY; CANCER GRADING; CHEMISTRY; CHI SQUARE DISTRIBUTION; CROATIA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG TUMOR; MALE; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL; TIME; TUMOR INVASION; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ASPARTIC ACID ENDOPEPTIDASES; BIOPSY; BRONCHOSCOPY; CHI-SQUARE DISTRIBUTION; CROATIA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NUCLEAR PROTEINS; PARAFFIN EMBEDDING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; RNA-BINDING PROTEINS; SURVIVAL ANALYSIS; TIME FACTORS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

MLCS; MLOWN;

EID: 84870054841     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-7-165     Document Type: Article

References (27)

1. Kerr KM. Classification of lung cancer: proposals for change?. Arch Pathol Lab Med 2012, 136:1190-1193. 10.5858/arpa.2012-0240-SA, 23020721.
2. Gabrielson E. Worldwide trends in lung cancer pathology. Respirology 2006, 11:533-538. 10.1111/j.1440-1843.2006.00909.x, 16916324.
3. Travis WD, Brambilla E, Noguchi M, Nicholson AG, Geisinger KR, Yatabe Y, Beer DG, Powell CA, Riely GJ, Van Schil PE, Garg K, Austin JH, Asamura H, Rusch VW, Hirsch FR, Scagliotti G, Mitsudomi T, Huber RM, Ishikawa Y, Jett J, Sanchez-Cespedes M, Sculier JP, Takahashi T, Tsuboi M, Vansteenkiste J, Wistuba I, Yang PC, Aberle D, Brambilla C, Flieder D, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol 2011, 6:244-285. 10.1097/JTO.0b013e318206a221, 21252716.
4. Edvards SL, Roberts C, McKean ME, Cockburn JS, Jeffrey RR, Kerr KM. Preoperative histological classification of primary lung cancer: accuracy of diagnosis and use of the non-small cell category. J Clin Pathol 2000, 53:537-540. 10.1136/jcp.53.7.537, 1731233, 10961178.
5. Travis WD, Rekhtman N, Riley GJ, Geisinger KR, Asamura H, Brambilla E, Garg K, Hirsch FR, Noguchi M, Powell CA, Rusch VW, Scagliotti G, Yatabe Y. Pathologic diagnosis of advanced lung cancer based on small biopsies and cytology: a paradigm shift. J Thorac Oncol 2010, 5:411-414. 10.1097/JTO.0b013e3181d57f6e, 20357614.
6. Jagirdar J. Application of immunohistochemistry to the diagnosis of primary and metastatic carcinoma to the lung. Arch Pathol Lab Med 2008, 132:384-396.
7. Terry J, Leung S, Laskin J, Leslie KO, Gown AM, Ionescu DN. Optimal immunohistochemical markers for distinguishing lung adenocarcinomas from squamous cell carcinomas in small tumor samples. Am J Surg Pathol 2010, 34:1805-1811. 10.1097/PAS.0b013e3181f7dae3, 21107086.
8. Turner BM, Cagle PT, Sainz IM, Fukuoka J, Shen SS, Jagirdar J. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid transcription factor 1 in the differential diagnosis of primary pulmonary carcinoma: evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med 2012, 136:163-171. 10.5858/arpa.2011-0320-OA, 22288963.
9. Barletta JA, Perner S, Iafrate AJ, Yeap BY, Weir BA, Johnson LA, Johnson BE, Meyerson M, Rubin MA, Travis WD, Loda M, Chirieac LR. Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma. J Cell Mol Med 2009, 13:1977-1986. 10.1111/j.1582-4934.2008.00594.x, 2830395, 19040416.
10. Stoll LM, Johnson MW, Gabrielson E, Askin F, Clark DP, Li QK. The utility of napsin-A in the identification of primary and metastatic lung adenocarcinoma among cytologically poorly differentiated carcinomas. Cancer Cytopathol 2010, 118:441-449. 10.1002/cncy.20108, 20830690.
11. Bishop JA, Sharma R, Illei PB. Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. Hum Pathol 2010, 41:20-25. 10.1016/j.humpath.2009.06.014, 19740516.
12. Findeis-Hosey J, Xu H. The use of insulin like-growth factor II messenger RNA binding protein-3 in diagnostic pathology. Hum Pathol 2011, 42:303-314. 10.1016/j.humpath.2010.06.003, 20970161.
13. Mueller-Pillasch F, Lacher U, Wallrapp C, Micha A, Zimmerhackl F, Hameister H, Varga G, Friess H, Buchler M, Beger HG, Vila MR, Adler G, Gress TM. Cloning a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene 1997, 14:2729-2733. 10.1038/sj.onc.1201110, 9178771.
14. King RL, Pasha T, Roullet MR, Zhang PJ, Bagg A. IMP-3 is differentially expressed in normal and neoplastic lymphoid tissue. Hum Pathol 2009, 40:1699-1705. 10.1016/j.humpath.2009.05.003, 19698973.
15. Lu D, Yang X, Jiiang NY, Woda BA, Liu Q, Dresser K, Mercurio AM, Rock KL, Jiang Z. IMP3, a new biomarker to predict progression of cervical intraepithelial neoplasia into invasive cancer. Am J Surg Pathol 2011, 35:1638-1645. 10.1097/PAS.0b013e31823272d4, 21997684.
16. Jiang Z, Chu PG, Woda BA, Rock KL, Liu O, Hsieh CC, Chen W, Duan HO, McDougal S, Wu CL. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma:a retrospective study. Lancet Oncol 2006, 7:556-564. 10.1016/S1470-2045(06)70732-X, 16814207.
17. Wang L, Li H, Xia Z, Lu J, Peng T. IMP3 is a novel biomarker to predict metastasis et progosis of gastric adenocarcinoma;a retrospective study. Chin Med J 2010, 123:3554-3558.
18. Xu H, Bourne PA, Spaulding BO, Wang HL. High-grade neuroendocrine carcinomas oft he lung express K homology domain containing protein overexpressed in cancer but carcinoid tumors do not. Hum Pathol 2007, 38:555-563. 10.1016/j.humpath.2006.11.011, 17316760.
19. Belleza G, Cavaliere A, Sidoni A. IMP3 expression in non-small cell lung cancer. Hum Pathol 2009, 40:1205-1206. 10.1016/j.humpath.2009.03.019, 19427669.
20. Findeis-Hosey JJ, Yang Q, Spaulding BO, Wang HL, Xu H. IMP3 expression is correlated with histologic grade of lung adenocarcinoma. Hum Pathol 2010, 41:477-484. 10.1016/j.humpath.2009.10.004, 20004948.
21. Barletta JA, Yeap BY, Chirieac LR. Prognostic significance of grading in lung adenocarcinoma. Cancer 2010, 116:659-669. 10.1002/cncr.24831, 2846761, 20014400.
22. Charloux A, Quoix E, Wolkove N, Small D, Pauli G, Kreisman H. Increasing incidence of lung adenocarcinoma: reality or artefact? A review of the epidemiology of lung adenocarcinoma. Int J Epidemiol 1997, 26:14-23. 10.1093/ije/26.1.14, 9126499.
23. Ji M, Zhang Y, Shi B, Hou P. Association of promoter methylation with histologic type and pleural indentation in non-small cell lung cancer (NSCLC). Diagn Pathol 2011, 6:48. 10.1186/1746-1596-6-48, 3123260, 21639921.
24. Sterlacci W, Savic S, Schmid T, Oberaigner W, Auberger J, Fiegl M, Tzankov A. Tissue-sparing application of the newly proposed IASLC/ATS/ERS classification of adenocarcinoma of the lung ahows practical diagnostic and prognostic impact. Am J Clin Pathol 2012, 137:946-956. 10.1309/AJCP77KMKJXNMPMS, 22586054.
25. Ohe M, Yokose T, Sakuma Y, Osanai S, Hasegawa C, Washimi K, Nawa K, Woo T, Hamanaka R, Nakayama H, Kameda Y, Yamada K, Isobe T. Stromal micropapillary pattern predominant lung adenocarcinoma - a report of two cases. Diagn Pathol 2011, 6:92. 10.1186/1746-1596-6-92, 3212918, 21955603.
26. Ohe M, Yokose T, Sakuma Y, Miyagi Y, Okamoto N, Osanai S, Hasegawa C, Nakayama H, Kameda Y, Yamada K, Isobe T. Stromal micropapillary component as a novel unfavorable prognostic factor of lung adenocarcinoma. Diagn Pathol 2012, 7:3. 10.1186/1746-1596-7-3, 3320518, 22225786.
27. Ueno T, Linder S, Elmberger G. Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma. British J Cancer 2003, 88:1229-1233.